The aim of this study was to evaluate the antimicrobial susceptibility of 25 K. pneumoniae strains isolated in 20062007 from 22 ICU patients in the Dr A. Jurasz University Hospital in Bydgoszcz. The group included the first K. pneumoniae isolates with MBL identified in Poland.
The study included 25 K. pneumoniae strains from 22 ICU patients. Except for four MBLs-positive, the strains were isolated from different patients and various samples: eight (32,0%) isolates were from blood and BAL (bronchoalveolar lavage), three were from wound swabs, two were from fistulae swab and urine samples, and single isolates were from the abdominal and peritoneal fluid. All isolates except those from wound and fistulae swabs were recovered as monocultures.
The isolates were identified with commercial ID32E tests (bioMérieux). The antimicrobial susceptibility tests were performed by the disk-diffusion method according to the recommendations of the Polish National Reference Centre for Antimicrobial Susceptibility Testing (Hryniewicz et al., 2006 According to the results of MBL testing, the study strains were divided into two subgroups: MBL-positive four strains and MBL-negative 21 isolates. Among MBL-negative 16 strains were ESBL-producing. The results of antimicrobial susceptibility testing are presented in Fig. 1 and Fig. 2 . All strains were resistant to ampicillin. The MBL-producers showed a high-level beta-lactam resistance pattern with resistance to all compounds except for aztreonam. Of the remaining antimicrobials tested, only gentamicin and tetracycline showed in vitro activity against these isolates.
The MBL-positive K. pneumoniae isolates were obtained from one patient and were recovered from a wound swab, urine, blood and abdominal fluid. MICs against the MBL-positive isolates were: > 32 µg/ml for imipenem and meropenem, 0.250.5 µg/ml for aztreonam, 23 µg/ml for gentamicin, 3264 mg/ml for amikacin. Tetracycline MICs varied from 0.5 µg/ml to 32 µg/ml. Ciprofloxacin MICs were 432 µg/ml for isolates from wound swab and abdominal fluid. The isolate from blood was found to carry a bla VIMlike family gene, located in a conjugative plasmid (data not shown).
MBL-producing Enterobacteriaceae have been increasingly isolated in recent years (Luzzaro et al., 2004; Toraman et al., 2004; Tórtola et al., 2005; Kassis-Chikhani et al., 2006) especially rapidly disseminating in hospitals in Greece (Giakkoupi et al., 2003; Pournaras et al., 2005) . Although MBLs hydrolyze all beta-lactams except for monobactams, enterobacterial isolates with these enzymes relatively frequently appear to be susceptible in vitro to various beta-lactams, including carbapenems (Walsh et al., 2005; Queenan and Bush, 2007) . The possibility of their use in such cases, however, has been a controversial issue (Souli et al., 2006) . Of note is the highlevel resistance phenotype observed with the MBL producers in our study.
A VIM-type MBL (VIM-1) was first described in a Pseudomonas aeruginosa strain from Verona, Italy, from 1996 (Cornaglia et al., 2000) . Currently 12 variants of these enzymes are known and they are divided into three groups: VIM-1-like, VIM-2-like and VIM-7. The VIM-1-like and VIM-2-like enzymes show around 90% identify at the amino-acid sequence level, and whereas VIM-2-like MBLs have been spreading mostly in P. aeruginosa, the VIM-1-like $-lactamases have been more characteristic for Enterobacteriaceae (Giakkoupi et al., 2003; Pournaras et al., 2005 , Walsh et al., 2005 . A preliminary further analysis suggested that the enzyme present in our K. pneumoniae isolates belonged to the VIM-1 group as well (data not shown).
To our knowledge, the four MBL producers from a single patient reported here have been the first MBL-positive K. pneumoniae isolates in Poland. Owing to their multi-drug and high-level resistance there have been almost no therapeutic options left. Identification of such organisms in a hospital, even for carriage should be a signal for implementation of the most stringent infection control procedures. Polish clinical microbiology laboratories should start routine testing for MBLs in Enterobacteriaceae.
